𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma

✍ Scribed by Yasuhiro Oki; Michinori Ogura; Harumi Kato; Ako Kikuchi; Hirofumi Taji; Yoshitoyo Kagami; Aya Oshiro; Akane Tsujimura; Kazuhito Yamamoto; Yasuo Morishima

Book ID
108584057
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
107 KB
Volume
0
Category
Article
ISSN
1347-9032

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Pixantrone dimaleate in combination with
Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma : Phase 1 study with a dose-expansion cohort
✍ Tomasz P. Srokowski; James E. Liebmann; Manuel R. Modiano; Gary I. Cohen; Barbar πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 166 KB πŸ‘ 2 views

## Abstract ## BACKGROUND: Pixantrone dimaleate (pixantrone) has been shown to have antitumor activity in leukemia and lymphoma in vitro models and to lack delayed cardiotoxicity associated with mitoxantrone in animal models. FND‐R, a combination regimen of fludarabine, mitoxantrone, dexamethasone

Phase II trial of etoposide and cisplati
Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non-Hodgkin's lymphoma: Cancer and leukemia group B study 8351
✍ Rybak, Mary Ellen ;Anderson, James ;Kaplan, Richard ;Budman, Daniel R. ;Vincigue πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 435 KB

## Abstract A phase‐II study was conducted by the Cancer and Leukemia Group B (CALGB) in patients with refractory and relapsed non‐Hodgkin's lymphoma (NHL) to assess the activity of the combination of etoposide and cisplatin. Sixty‐five patients were entered on study, and 51 patients were evaluated

Equitoxicity of bolus and infusional eto
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)
✍ Carsten Zwick; Josef Birkmann; Norma Peter; Heinrich Bodenstein; Roland Fuchs; M πŸ“‚ Article πŸ“… 2008 πŸ› Springer 🌐 English βš– 259 KB